| Literature DB >> 24525422 |
João Ananias Machado-Filho1, Alyne Oliveira Correia1, Anyssa Brilhante Aires Montenegro1, Maria Elizabeth Pereira Nobre1, Gilberto Santos Cerqueira2, Kelly Rose Tavares Neves2, Maria da Graça Naffah-Mazzacoratti3, Esper Abrão Cavalheiro3, Gerly Anne de Castro Brito2, Glauce Socorro de Barros Viana4.
Abstract
Several lines of evidences have shown the inversion association between coffee consumption and Parkinson's disease (PD) development. Caffeine is a methylxanthine known as a non-selective inhibitor of A2A and A1 adenosine receptors in the brain and shown to be a neuroprotective drug. The objectives were to study caffeine effects in a unilateral 6-OHDA model of PD in rats. Male rats were divided into the following groups: sham-operated (SO), striatal 6-OHDA-lesioned and 6-OHDA-lesioned and treated for 2 weeks with caffeine (10 and 20mg/kg, p.o.). Then, animals were subjected to behavioral (open field and apomorphine-induced rotations), neurochemical (striatal determinations of DA and DOPAC), histological (cresyl violet staining) and immunohistochemical (TH, TNF-α, IL-1β and HDAC) evaluations. The results showed that while the 6-OHDA group presented a decreased locomotor activity and a high number of apomorphine-induced rotations, these behaviors were partially blocked by caffeine. Caffeine itself increased DA contents and reversed the decrease in striatal DA observed in the 6-OHDA-lesioned group. Furthermore, it improved the hippocampal neuronal viability and significantly increased TH immunoreactivity in the striatum of the 6-OHDA-lesioned group. In addition, caffeine treatment also decreased the number of immunopositive cells for HDAC and pro-inflammatory cytokines TNF-α and IL-1β. All these effects points out to a neuroprotective effect of caffeine and its potential benefit in the prevention and treatment of PD.Entities:
Keywords: 6-OHDA model; Behavior; Caffeine; Neuroprotection; Parkinson's disease; Pro-inflammatory cytokine
Mesh:
Substances:
Year: 2014 PMID: 24525422 DOI: 10.1016/j.bbr.2014.01.051
Source DB: PubMed Journal: Behav Brain Res ISSN: 0166-4328 Impact factor: 3.332